Market

Can Upadacitinib Redefine the Regulatory Path for Vitiligo?
Research & Development Can Upadacitinib Redefine the Regulatory Path for Vitiligo?

Historical failures in the vitiligo pipeline, such as the cancellation of the AC##4 trial in 2016, highlight the difficulty of establishing a global site network. The recent publication of the Viti-Up Phase 3 clinical trial results in The Lancet marks a transformative moment for dermatologic

Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?
Research & Development Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?

For the 15,000 Americans living with Duchenne muscular dystrophy, the three-month regulatory delay represents a critical window where irreversible physical decline remains a constant threat. This extension, moving the target decision date from August to November 22, 2026, occurred after the Food

How Is COFEPRIS Digitizing Medical Device Regulation?
Management & Regulatory How Is COFEPRIS Digitizing Medical Device Regulation?

This digital initiative addresses long-standing inefficiencies by providing a public mechanism to verify the legal status of medical devices sold throughout the country. For many years, the Mexican medical device market struggled with a lack of transparency, where paper-based records led to

Can Biomanufacturing Solve the Global Cocoa Crisis?
Management & Regulatory Can Biomanufacturing Solve the Global Cocoa Crisis?

Utilizing brewery-style fermentation tanks to cultivate cocoa cells allows manufacturers to maintain 100 percent supply-chain stability regardless of unpredictable weather patterns. This innovative methodology, pioneered by Boston-based biotechnology leader GALY, arrives at a critical juncture for

SkyLabs to Launch IPO as Global Medical Data Powerhouse
Tech & Innovation SkyLabs to Launch IPO as Global Medical Data Powerhouse

Securing CE-MDR clearance has allowed SkyLabs to establish robust distribution networks in the United Kingdom and throughout mainland Europe's healthcare systems. This strategic milestone marks a significant step for the South Korean technology pioneer as it prepares for its transition to the

How Can Mankind Pharma Balance ESG Growth and Global Scaling?
Management & Regulatory How Can Mankind Pharma Balance ESG Growth and Global Scaling?

The company reported a consolidated revenue of ₹4,031 crore for the first quarter of fiscal year 2027, reflecting a significant 12.89% annual growth. This financial achievement underscores the robust performance of its domestic portfolio, which continues to outpace the general Indian pharmaceutical

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later